Total Payments
$846.94
2024 Payments
$410.06
Companies
24
Transactions
38
Medicare Patients
5,023
Medicare Billing
$634,359
Payment Breakdown by Category
Food & Beverage$611.61 (72.2%)
Education$235.33 (27.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $611.61 | 33 | 72.2% |
| Education | $235.33 | 5 | 27.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $198.00 | 2 | $0 (2022) |
| Celgene Corporation | $86.37 | 5 | $0 (2024) |
| ABBVIE INC. | $84.63 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $50.14 | 3 | $0 (2024) |
| Gilead Sciences, Inc. | $45.28 | 3 | $0 (2024) |
| Daiichi Sankyo Inc. | $45.21 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $40.33 | 2 | $0 (2024) |
| Genmab U.S., Inc. | $30.97 | 1 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $25.59 | 1 | $0 (2024) |
| SOBI, INC | $22.79 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $410.06 | 22 | ABBVIE INC. ($61.00) |
| 2023 | $173.64 | 9 | Celgene Corporation ($53.41) |
| 2022 | $212.92 | 3 | Amgen Inc. ($198.00) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $26.11 | 2 | E.R. Squibb & Sons, L.L.C. ($13.12) |
| 2018 | $12.29 | 1 | Seattle Genetics, Inc. ($12.29) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: Oncology | ||||||
| 06/18/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $17.68 | General |
| 06/13/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.28 | General |
| Category: Hematology | ||||||
| 04/29/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.68 | General |
| 04/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 04/04/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $30.97 | General |
| Category: Oncology | ||||||
| 04/02/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/26/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.97 | General |
| 03/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: ONCOLOGY | ||||||
| 02/28/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $15.97 | General |
| 02/13/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: Oncology | ||||||
| 02/06/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $13.97 | General |
| Category: Oncology | ||||||
| 02/01/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Immunology | ||||||
| 01/24/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: ONCOLOGY | ||||||
| 01/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.68 | General |
| 01/03/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2023 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: BioOncology | ||||||
| 10/03/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 905 | 1,378 | $445,107 | $106,996 |
| 2022 | 9 | 944 | 1,460 | $367,144 | $105,740 |
| 2021 | 9 | 1,059 | 1,756 | $376,541 | $114,203 |
| 2020 | 30 | 2,115 | 22,279 | $1.5M | $307,420 |
Total Patients
5,023
Total Services
26,873
Medicare Billing
$634,359
Procedure Codes
74
All Medicare Procedures & Services
74 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 260 | 462 | $134,706 | $32,275 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 110 | 224 | $95,888 | $24,385 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 125 | 208 | $60,528 | $14,276 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 54 | 88 | $37,782 | $9,575 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 134 | 153 | $28,668 | $6,599 | 23.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 48 | 48 | $29,564 | $6,548 | 22.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $15,724 | $3,155 | 20.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 64 | 65 | $12,170 | $2,939 | 24.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $11,086 | $2,384 | 21.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 22 | $6,226 | $2,037 | 32.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 22 | $4,430 | $1,354 | 30.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $6,383 | $852.15 | 13.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 15 | 16 | $1,952 | $616.48 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 189 | 397 | $95,389 | $27,578 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 134 | 271 | $64,305 | $18,388 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 80 | 124 | $41,176 | $13,735 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 204 | 256 | $41,115 | $11,419 | 27.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 60 | 97 | $32,424 | $10,906 | 33.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 107 | 123 | $19,724 | $5,771 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 47 | 47 | $22,136 | $4,874 | 22.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $20,030 | $4,750 | 23.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 28 | $6,608 | $2,257 | 34.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 33 | $5,445 | $1,848 | 33.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 17 | 17 | $7,974 | $1,811 | 22.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 21 | 21 | $7,035 | $1,378 | 19.6% |
About Dr. Birgit Arb, MD
Dr. Birgit Arb, MD is a Medical Oncology healthcare provider based in Pulaski, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1669466405.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Birgit Arb, MD has received a total of $846.94 in payments from pharmaceutical and medical device companies, with $410.06 received in 2024. These payments were reported across 38 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($611.61).
As a Medicare-enrolled provider, Arb has provided services to 5,023 Medicare beneficiaries, totaling 26,873 services with total Medicare billing of $634,359. Data is available for 4 years (2020–2023), covering 74 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Pulaski, VA
- Active Since 09/08/2005
- Last Updated 09/30/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1669466405
Products in Payments
- VENCLEXTA (Drug) $84.63
- Enhertu (Drug) $45.21
- OJJAARA (Drug) $40.33
- Tivdak (Drug) $30.97
- LIBTAYO (Biological) $25.59
- VONJO (Drug) $22.79
- Lenvima (Drug) $22.69
- Venclexta (Biological) $18.68
- Pomalyst (Drug) $18.25
- IBRANCE (Drug) $17.65
- OPDUALAG (Drug) $17.58
- ENHERTU (Biological) $17.37
- CABOMETYX (Drug) $16.93
- BRUKINSA (Drug) $16.30
- REBLOZYL (Biological) $15.28
- ZEPZELCA (Drug) $15.28
- LYNPARZA (Drug) $14.80
- MONJUVI (Drug) $13.97
- Fabhalta (Drug) $13.87
- Oncology (Device) $12.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.